<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EXFORGE - amlodipine besylate and valsartan tablet, film coated </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use</span><span class="Bold"> Exforge</span> <span class="Bold">safely and effectively</span><span class="Bold">. </span><span class="Bold">See full prescribing information for</span><span class="Bold"> Exforge</span><span class="Bold">.</span><br><span class="Bold">Exforge (amlodipine and valsartan) Tablets</span><br><span class="Bold">Initial U.S. Approval:</span><span class="Bold"> 2007</span><br>
</div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING:</span><span class="Bold"> </span><span class="Bold">AVOID </span><span class="Bold">USE IN PREGNANCY</span><span class="Bold"> </span>
</h1>
<h1 class="Warning">
<span class="Bold Italics">See full prescribing information for complete boxed warning</span><span class="Bold Italics">.</span>
</h1>
<p class="Highlighta"><span class="Bold">When pregnancy is detected,</span><span class="Bold"> discontinue </span><span class="Bold">Exforge as soon as possible.</span><span class="Bold"> </span><span class="Bold">D</span><span class="Bold">rugs that act directly on the renin-angiotensin system can cause injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. (<a href="#s5p1">5.1</a>)</span> </p>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING:</span><span class="Bold"> </span><span class="Bold">AVOID </span><span class="Bold">USE IN PREGNANCY</span><span class="Bold"> </span>
</h1>
<h1 class="Warning">
<span class="Bold Italics">See full prescribing information for complete boxed warning</span><span class="Bold Italics">.</span>
</h1>
<p class="Highlighta"><span class="Bold">When pregnancy is detected,</span><span class="Bold"> discontinue </span><span class="Bold">Exforge as soon as possible.</span><span class="Bold"> </span><span class="Bold">D</span><span class="Bold">rugs that act directly on the renin-angiotensin system can cause injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. (<a href="#s5p1">5.1</a>)</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Exforge is the combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB). Exforge is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>:  (<a href="#section-1">1</a>)</p>
<ul class="Disc">
<li>In patients not adequately controlled on monotherapy (1)<br>
</li>
<li>As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals (1).</li>
</ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<span class="Bold">General Considerations</span>:<ul class="Disc">
<li>Majority of effect attained within 2 weeks (<a href="#s2p1">2.1</a>)<br>
</li>
<li>May be administered with other antihypertensive agents (<a href="#s2p1">2.1</a>)</li>
</ul>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span><ul class="Disc">
<li>May be used as add-on therapy for patients not controlled on monotherapy (<a href="#s2p2">2.2</a>)<br>
</li>
<li>Patients who experience dose-limiting adverse reactions on monotherapy may be switched to Exforge containing a lower dose of that component (<a href="#s2p2">2.2</a>)<br>
</li>
<li>May be substituted for titrated components (<a href="#s2p3">2.3</a>)<br>
</li>
<li>When used as initial therapy: Initiate with 5/160 mg, then titrate upwards as necessary to a maximum of 10/320 mg once daily (<a href="#s2p4">2.4</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>Tablets (amlodipine/valsartan mg): 5/160, 10/160, 5/320, 10/320 (<a href="#s3">3</a>)</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>None</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Avoid fetal or neonatal exposure (<a href="#s5p1">5.1</a>)<br>
</li>
<li>Assess for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. (<a href="#s5p2">5.2</a>)<br>
</li>
<li>Warn patients with severe obstructive <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> about the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or increased angina (<a href="#s5p3">5.3</a>)<br>
</li>
<li>Titrate slowly in patients with impaired hepatic (<a href="#s5p4">5.4</a>) or severely impaired renal (<a href="#s5p5">5.5</a>) function</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">In placebo-controlled clinical trials, discontinuation due to side effects occurred in 1.8% of patients in the Exforge-treated patients and 2.1% in the placebo-treated group. The most common reasons for discontinuation of therapy with Exforge were <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. The adverse experiences that occurred in clinical trials (≥2% of patients) at a higher incidence than placebo included <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. (<a href="#s6">6</a>) </p>
<span class="Bold"><br><br>To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>If simvastatin is co-administered with amlodipine, do not exceed doses greater than 20 mg daily of simvastatin (<a href="#s7">7</a>)</li>
<li>NSAIDS use may lead to increased risk of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and loss of anti-hypertensive effect (<a href="#s7">7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>Start amlodipine or add amlodipine at 2.5 mg in patients ≥75 years old or in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#s8p5">8.5</a>)<p class="Highlighta"><span class="Bold">Nursing Mothers</span>: Choose breastfeeding or Exforge therapy, but not both. (<a href="#s8p3">8.3</a>) </p>
<br><br>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 1/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: </span><span class="Bold">AVOID </span><span class="Bold">USE IN PREGNANCY</span></a></h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">INDICATIONS AND USAGE</span></a></h1>
<h2><a href="#section-1.1" class="toc"><span class="Bold">1.1</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></a></h2>
<h1><a href="#section-2" class="toc"><span class="Bold">2</span><span class="Bold">  </span><span class="Bold">DOSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1 General Consideration</span><span class="Bold">s</span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2 Add-on Therapy</span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="Bold">2.3 Replacement Therapy</span></a></h2>
<h2><a href="#section-2.4" class="toc"><span class="Bold">2.4 Initial Therapy</span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4  </span><span class="Bold"></span><span class="Bold">CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1 </span><span class="Bold">Fetal/Neonatal Morbidity and Mortality</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3 </span><span class="Bold">Risk of </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span><span class="Bold"> or Increased Angina</span><span class="Bold"> </span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4 Impaired Hepatic Function</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span> - <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.6 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">ADVERSE REACTIONS</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1 Clinical Trials Experience</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2 </span><span class="Bold">Post</span><span class="Bold">m</span><span class="Bold">arketing Experience</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7</span><span class="Bold">  </span><span class="Bold">DRUG INTERACTIONS</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.1 Drug/Drug Interactions</span></a></h2>
<h2><a href="#section-7.2" class="toc"><span class="Bold">7.2 CYP 450 Interactions</span></a></h2>
<h2><a href="#section-7.3" class="toc"><span class="Bold">7.3 </span><span class="Bold">Transporters</span></a></h2>
<h2><a href="#section-7.4" class="toc"><span class="Bold">7.4 Clinical Laboratory Findings</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8</span><span class="Bold">  </span><span class="Bold">USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1 Pregnancy</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.2 Labor and Delivery</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.3 Nursing Mothers</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.4 Pediatric Use</span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.5 Geriatric Use</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10</span><span class="Bold">  </span><span class="Bold">OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11</span><span class="Bold">  </span><span class="Bold">DESCRIPTION</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12</span><span class="Bold">  </span><span class="Bold">CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold">12.1 Mechanism of Action</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold">12.2 Pharmacodynamics</span></a></h2>
<h2><a href="#section-11.3" class="toc"><span class="Bold">12.3 Pharmacokinetics</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13</span><span class="Bold">  </span><span class="Bold">NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">13.1 Carcinogenesis</span><span class="Bold">,</span><span class="Bold"> Mutagenesis</span><span class="Bold">,</span><span class="Bold"> Impairment of Fertility</span></a></h2>
<h2><a href="#section-12.2" class="toc"><span class="Bold">13.3 Developmental Toxicity </span><span class="Bold">Studies</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14</span><span class="Bold">  </span><span class="Bold">CLINICAL STUDIES</span></a></h1>
<h1><a href="#section-14" class="toc"><span class="Bold">16</span><span class="Bold">  </span><span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">17</span><span class="Bold">  </span><span class="Bold">PATIENT COUNSELING INFORMATION</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1>
<span class="Bold">WARNING: </span><span class="Bold">AVOID </span><span class="Bold">USE IN PREGNANCY</span>
</h1>
<p class="First"><span class="Bold">When pregnancy is detected, </span><span class="Bold">discontinue </span><span class="Bold">Exforge as soon as possible</span><span class="Bold">. </span><span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus</span><span class="Bold">. </span><span class="Bold">[</span><span class="Bold Italics">See</span><span class="Bold"> </span><span class="Bold Italics">W</span><span class="Bold Italics">arnings</span><span class="Bold Italics"> </span><span class="Bold Italics">and</span><span class="Bold Italics"> P</span><span class="Bold Italics">recautions</span><span class="Bold Italics"> </span><span class="Bold Italics">(5.1)</span><span class="Bold">]</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>
<span class="Bold">1</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">INDICATIONS AND USAGE</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<h2>
<span class="Bold">1.1</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span>
</h2>
<p class="First">Exforge (amlodipine and valsartan) is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p>Exforge may be used in patients whose blood pressure is not adequately controlled on either monotherapy. </p>
<p>Exforge may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.</p>
<p>The choice of Exforge as initial therapy for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the lowest dose of Exforge.</p>
<p>Patients with stage 2 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (moderate or severe) are at a relatively higher risk for cardiovascular events (such as <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>), <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk.</p>
<p>Data from the high-dose multifactorial study [<span class="Italics">see Clinical </span><span class="Italics">Studies</span><span class="Italics"> (14)</span>] provide estimates of the probability of reaching a blood pressure goal with Exforge compared to amlodipine or valsartan monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Exforge 10/320 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. </p>
<a name="i5f444f12-46a6-42bf-8b08-36e6aabb8195"></a><table>
<col width="367">
<col width="367">
<tbody class="Headless">
<tr class="First">
<td align="center">
<img alt="Figure 1: Probability of Achieving Systolic Blood Pressure &lt;140 mmHg at Week 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=15ba7c1c-dd10-4d09-b6e2-284c1b67f4da&amp;name=exforge-01.jpg"><br><span class="Bold">Figure 1:</span><span class="Bold"> </span><span class="Bold">Probability of Achieving Systolic Blood Pressure &lt;140 mmHg at Week 8</span><br>
</td>
<td align="center">
<img alt="Figure 2: Probability of Achieving Diastolic Blood Pressure &lt;90 mmHg at Week 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=15ba7c1c-dd10-4d09-b6e2-284c1b67f4da&amp;name=exforge-02.jpg"><br><span class="Bold">Figure 2:</span><span class="Bold"> </span><span class="Bold">Probability of Achieving Diastolic Blood Pressure</span><span class="Bold"> </span><span class="Bold">&lt;90 mmHg at Week 8</span><br>
</td>
</tr>
<tr class="Last">
<td>
<img alt="Figure 3: Probability of Achieving Systolic Blood Pressure &lt;130 mmHg at Week 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=15ba7c1c-dd10-4d09-b6e2-284c1b67f4da&amp;name=exforge-03.jpg"><br><span class="Bold">Figure 3:</span><span class="Bold"> </span><span class="Bold">Probability of Achieving Systolic Blood Pressure &lt;130 mmHg at Week 8</span><br>
</td>
<td>
<img alt="Figure 4: Probability of Achieving Diastolic Blood Pressure &lt;80 mmHg at Week 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=15ba7c1c-dd10-4d09-b6e2-284c1b67f4da&amp;name=exforge-04.jpg"><br><span class="Bold">Figure 4:</span><span class="Bold"> </span><span class="Bold">Probability of Achieving Diastolic Blood Pressure</span><span class="Bold"> </span><span class="Bold">&lt;80 mmHg at Week 8</span><br>
</td>
</tr>
</tbody>
</table>
<p>For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 67% likelihood of achieving a goal of &lt;140 mmHg (systolic) and 80% likelihood of achieving &lt;90 mmHg (diastolic) on amlodipine alone, and the likelihood of achieving these goals on valsartan alone is about 47% (systolic) or 62% (diastolic). The likelihood of achieving these goals on Exforge rises to about 80% (systolic) or 85% (diastolic). The likelihood of achieving these goals on placebo is about 28% (systolic) or 37% (diastolic).</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>
<span class="Bold">2</span><span class="Bold">  </span><span class="Bold">DOSAGE AND ADMINISTRATION</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p1"></a><a name="section-2.1"></a><p></p>
<h2>
<span class="Bold">2.1 General Consideration</span><span class="Bold">s</span>
</h2>
<p class="First">Amlodipine is an effective treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in once daily doses of 2.5 mg to 10 mg while valsartan is effective in doses of 80 mg to 320 mg. In clinical trials with once daily Exforge (amlodipine and valsartan) using amlodipine doses of 5 mg to 10 mg and valsartan doses of 160 mg to 320 mg, the antihypertensive effects increased with increasing doses.</p>
<p>The hazards [<span class="Italics">see W</span><span class="Italics">arnings and Precautions(5)</span>] of valsartan are generally independent of dose; those of amlodipine are a mixture of dose-dependent phenomena (primarily <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>) and dose-independent phenomena, the former much more common than the latter [<span class="Italics">s</span><span class="Italics">ee</span> <span class="Italics">Adverse Reactions</span> <span class="Italics">(6)</span>].</p>
<p>The majority of the antihypertensive effect is attained within 2 weeks after initiation of therapy or a change in dose. The dosage can be increased after 1 to 2 weeks of therapy to a maximum of one 10/320 mg tablet once daily as needed to control blood pressure [<span class="Italics">s</span><span class="Italics">ee</span> <span class="Italics">Clinical Studies (14)</span>].</p>
<p>Exforge may be administered with or without food.</p>
<p>Exforge may be administered with other antihypertensive agents.</p>
<p><span class="Bold">Elderly patients</span>: Because of decreased clearance of amlodipine, therapy should usually be initiated at 2.5 mg.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>: No initial dosage adjustment is required for patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Titrate slowly in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>: No initial dosage adjustment is required for patients with mild or moderate liver insufficiency. Titrate slowly in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p2"></a><a name="section-2.2"></a><p></p>
<h2><span class="Bold">2.2 Add-on Therapy</span></h2>
<p class="First">A patient whose blood pressure is not adequately controlled with amlodipine (or another dihydropyridine calcium-channel blocker) alone or with valsartan (or another angiotensin II receptor blocker) alone may be switched to combination therapy with Exforge. </p>
<p>A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Exforge containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. The clinical response to Exforge should be subsequently evaluated and if blood pressure remains uncontrolled after 3 to 4 weeks of therapy, the dose may be titrated up to a maximum of 10/320 mg. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p3"></a><a name="section-2.3"></a><p></p>
<h2><span class="Bold">2.3 Replacement Therapy</span></h2>
<p class="First">For convenience, patients receiving amlodipine and valsartan from separate tablets may instead wish to receive tablets of Exforge containing the same component doses. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p4"></a><a name="section-2.4"></a><p></p>
<h2><span class="Bold">2.4 Initial Therapy</span></h2>
<p class="First">A patient may be initiated on Exforge if it is unlikely that control of blood pressure would be achieved with a single agent. The usual starting dose is Exforge 5/160 mg once daily in patients who are not volume-depleted.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>
<span class="Bold">3</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">DOSAGE FORMS AND STRENGTHS</span>
</h1>
<p class="First">5/160 mg tablets, debossed with NVR/ECE (side 1/side 2)</p>
<p>10/160 mg tablets, debossed with NVR/UIC</p>
<p>5/320 mg tablets, debossed with NVR/CSF</p>
<p>10/320 mg tablets, debossed with NVR/LUF</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>
<span class="Bold">4  </span><span class="Bold"></span><span class="Bold">CONTRAINDICATIONS</span>
</h1>
<p class="First"><span class="Xmchange"></span>None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>
<span class="Bold">5</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">WARNINGS AND PRECAUTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p1"></a><a name="section-5.1"></a><p></p>
<h2>
<span class="Bold">5.1 </span><span class="Bold">Fetal/Neonatal Morbidity and Mortality</span>
</h2>
<p class="First">Exforge can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus<span class="Italics">.</span></p>
<p>Drugs that act on the renin angiotensin system can cause fetal and neonatal morbidity and mortality when used in pregnancy. In several dozen published cases, ACE inhibitor use during the second and third trimesters of pregnancy was associated with fetal and neonatal injury, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, neonatal skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, reversible or <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span>, and death [<span class="Italics">s</span><span class="Italics">ee Use in Specific Populations (8.1)</span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p2"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></h2>
<p class="First">Excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was seen in 0.4% of patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncomplicated hypertension</span> treated with Exforge in placebo-controlled studies. In patients with an activated renin-angiotensin system, such as volume-and/or salt-depleted patients receiving high doses of diuretics, symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur in patients receiving angiotensin receptor blockers. <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Volume depletion</span> should be corrected prior to administration of Exforge. Treatment with Exforge should start under close medical supervision.</p>
<p>Initiate therapy cautiously in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and in patients undergoing surgery or dialysis. Patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> patients given valsartan commonly have some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> usually is not necessary when dosing instructions are followed. In controlled trials in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients, the incidence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in valsartan-treated patients was 5.5% compared to 1.8% in placebo-treated patients. In the Valsartan in <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> Trial (VALIANT), <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> patients led to permanent discontinuation of therapy in 1.4% of valsartan-treated patients and 0.8% of captopril-treated patients. </p>
<p>Since the vasodilation induced by amlodipine is gradual in onset, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">acute hypotension</span> has rarely been reported after oral administration. Nonetheless, caution, as with any other peripheral vasodilator, should be exercised when administering amlodipine, particularly in patients with severe <span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">aortic stenosis</span>. </p>
<p>If excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs with Exforge, the patient should be placed in a supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p3"></a><a name="section-5.3"></a><p></p>
<h2>
<span class="Bold">5.3 </span><span class="Bold">Risk of </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span><span class="Bold"> or Increased Angina</span><span class="Bold"> </span>
</h2>
<p class="First">Rarely, patients, particularly those with severe obstructive <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, have developed documented increased frequency, duration or severity of angina or <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> on starting calcium channel blocker therapy or at the time of dosage increase. The mechanism of this effect has not been elucidated. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p4"></a><a name="section-5.4"></a><p></p>
<h2><span class="Bold">5.4 Impaired Hepatic Function</span></h2>
<p class="First"><span class="Bold Italics">Studies with </span><span class="Bold Italics">A</span><span class="Bold Italics">mlodipine: </span>Amlodipine is extensively metabolized by the liver and the plasma elimination half-life (t½) is 56 hours in patients with impaired hepatic function, therefore, caution should be exercised when administering amlodipine to patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p><span class="Bold Italics">Studies with </span><span class="Bold Italics">V</span><span class="Bold Italics">alsartan:</span> As the majority of valsartan is eliminated in the bile, patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, including patients with biliary obstructive disorders, showed lower valsartan clearance (higher AUCs). Care should be exercised in administering valsartan to these patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p5"></a><a name="section-5.5"></a><p></p>
<h2><span class="Bold">5.5 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span> - <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></h2>
<p class="First">In studies of ACE inhibitors in hypertensive patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, increases in serum creatinine or blood urea nitrogen have been reported. In a 4-day trial of valsartan in 12 hypertensive patients with <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">unilateral renal artery stenosis</span>, no significant increases in serum creatinine or blood urea nitrogen were observed. There has been no long-term use of valsartan in patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, but an effect similar to that seen with ACE inhibitors should be anticipated. </p>
<p>As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may occur particularly in volume depleted patients. In patients with severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and (rarely) with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Similar outcomes have been reported with valsartan. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p6"></a><a name="section-5.6"></a><p></p>
<h2><span class="Bold">5.6 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></span></h2>
<p class="First"><span class="Bold Italics">Studies with </span><span class="Bold Italics">A</span><span class="Bold Italics">mlodipine: </span>In general, calcium channel blockers should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Amlodipine (5-10 mg per day) has been studied in a placebo-controlled trial of 1,153 patients with NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> on stable doses of ACE inhibitor, digoxin, and diuretics. Follow-up was at least 6 months, with a mean of about 14 months. There was no overall adverse effect on survival or cardiac morbidity (as defined by life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, or hospitalization for worsened <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>). Amlodipine has been compared to placebo in four 8-12 week studies of patients with NYHA class II/III <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, involving a total of 697 patients. In these studies, there was no evidence of worsened <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> based on measures of exercise tolerance, NYHA classification, symptoms, or LVEF.</p>
<p><span class="Bold Italics">Studies with </span><span class="Bold Italics">V</span><span class="Bold Italics">alsartan:</span> Some patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> have developed increases in blood urea nitrogen, serum creatinine, and potassium on valsartan. These effects are usually minor and transient, and they are more likely to occur in patients with pre-existing <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Dosage reduction and/or discontinuation of the diuretic and/or valsartan may be required. In the Valsartan <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> Trial, in which 93% of patients were on concomitant ACE inhibitors, treatment was discontinued for elevations in creatinine or potassium (total of 1.0% on valsartan vs. 0.2% on placebo). In the Valsartan in <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> Trial (VALIANT), discontinuation due to various types of renal dysfunction occurred in 1.1% of valsartan-treated patients and 0.8% of captopril-treated patients. Evaluation of patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> should always include assessment of renal function. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>
<span class="Bold">6</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">ADVERSE REACTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6p1"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">6.1 Clinical Trials Experience</span></h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.</p>
<p><span class="Bold Italics">Studies with </span><span class="Bold Italics">Exforge</span><span class="Bold Italics">:</span></p>
<p>Exforge has been evaluated for safety in over 2,600 patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; over 1,440 of these patients were treated for at least 6 months and over 540 of these patients were treated for at least one year. Adverse reactions have generally been mild and transient in nature and have only infrequently required discontinuation of therapy.</p>
<p>The overall frequency of adverse reactions was neither dose-related nor related to gender, age, or race. In placebo-controlled clinical trials, discontinuation due to side effects occurred in 1.8% of patients in the Exforge-treated patients and 2.1% in the placebo-treated group. The most common reasons for discontinuation of therapy with Exforge were <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> (0.4%), and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> (0.2%).</p>
<p>The adverse reactions that occurred in placebo-controlled clinical trials in at least 2% of patients treated with Exforge but at a higher incidence in amlodipine/valsartan patients (n=1,437) than placebo (n=337) included <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> (5.4% vs. 3.0%), <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (4.3% vs. 1.8%), <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> (2.9% vs 2.1%) and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (2.1% vs 0.9%).</p>
<p>Orthostatic events (<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>) were seen in less than 1% of patients.</p>
<p>Other adverse reactions that occurred in placebo-controlled clinical trials with Exforge (≥ 0.2%) are listed below. It cannot be determined whether these events were causally related to Exforge. </p>
<p><span class="Bold Italics">Blood and Lymphatic System Disorders:</span> <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span></p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Bold Italics">Ear and Labyrinth Disorders: </span><span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">Ear pain</span></p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span></p>
<p><span class="Bold Italics">General Disorders and Administration Site Conditions: </span><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">pitting edema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: </span>Seasonal allergies</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>:</span> <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="24978" conceptname="Chronic adenotonsillitis">pharyngotonsillitis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis acute</span>, <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> </p>
<p><span class="Bold Italics">Injury</span><span class="Bold Italics"> and</span><span class="Bold Italics"> <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span></span>: <span class="product-label-link" type="condition" conceptid="4249170" conceptname="Epicondylitis">Epicondylitis</span>, <span class="product-label-link" type="condition" conceptid="30234" conceptname="Neck sprain">joint sprain</span>, <span class="product-label-link" type="condition" conceptid="444130" conceptname="Injury of foot">limb injury</span></p>
<p><span class="Bold Italics">Metabolism and Nutrition Disorders: </span><span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout</span>, non-insulin dependent <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span></p>
<p><span class="Bold Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>, <span class="product-label-link" type="condition" conceptid="4092930" conceptname="Musculoskeletal chest pain">musculoskeletal chest pain</span></p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="372409" conceptname="Sciatica">sciatica</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="77639" conceptname="Diffuse cervicobrachial syndrome">cervicobrachial syndrome</span>, <span class="product-label-link" type="condition" conceptid="380094" conceptname="Carpal tunnel syndrome">carpal tunnel syndrome</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4172302" conceptname="Sinus headache">sinus headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span></p>
<p><span class="Bold Italics">Psychiatric Disorders: </span><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></p>
<p><span class="Bold Italics">Renal and Urinary Disorders:</span> <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span></p>
<p><span class="Bold Italics">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile dysfunction</span></p>
<p><span class="Bold Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">sinus congestion</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">productive cough</span>, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span></p>
<p><span class="Bold Italics">Skin and Subcutaneous Tissue Disorders: </span><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span></p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span></p>
<p>Isolated cases of the following clinically notable adverse reactions were also observed in clinical trials: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">exanthema</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p><span class="Bold Italics">Studies with Amlodipine:</span></p>
<p>Norvasc<span class="Sup">®</span><span class="Sup">*</span> has been evaluated for safety in more than 11,000 patients in U.S. and foreign clinical trials. Other adverse events that have been reported &lt;1% but &gt;0.1% of patients in controlled clinical trials or under conditions of open trials or marketing experience where a causal relationship is uncertain were:</p>
<p><span class="Bold Italics">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> (including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>), <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span></p>
<p><span class="Bold Italics">Central and Peripheral Nervous System:</span> <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy peripheral</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></p>
<p><span class="Bold Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, gingival <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span></p>
<p><span class="Bold Italics">General:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></p>
<p><span class="Bold Italics">Musculoskeletal System: </span><span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span></p>
<p><span class="Bold Italics">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> (male and female), <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span></p>
<p><span class="Bold Italics">Respiratory System: </span><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p><span class="Bold Italics">Skin and Appendages: </span><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculopapular</p>
<p><span class="Bold Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></p>
<p><span class="Bold Italics">Urinary System:</span> micturition frequency, micturition disorder, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span></p>
<p><span class="Bold Italics">Autonomic Nervous System: </span><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span></p>
<p><span class="Bold Italics">Metabolic and Nutritional:</span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span></p>
<p><span class="Bold Italics">Hemopoietic:</span> <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p>Other events reported with amlodipine at a frequency of ≤0.1% of patients include: <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, pulse irregularity, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, skin dryness, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, abnormal visual accommodation, and <span class="product-label-link" type="condition" conceptid="4180937" conceptname="Xerophthalmia">xerophthalmia</span>. Other reactions occurred sporadically and cannot be distinguished from medications or concurrent disease states such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and angina.</p>
<p>Adverse reactions reported for amlodipine for indications other than <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> may be found in the prescribing information for Norvasc.</p>
<p><span class="Bold Italics">Studies with Valsartan:</span></p>
<p>Diovan<span class="Sup">®</span> has been evaluated for safety in more than 4,000 hypertensive patients in clinical trials. In trials in which valsartan was compared to an ACE inhibitor with or without placebo, the incidence of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span> was significantly greater in the ACE inhibitor group (7.9%) than in the groups who received valsartan (2.6%) or placebo (1.5%). In a 129 patient trial limited to patients who had had <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span> when they had previously received ACE inhibitors, the incidences of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> in patients who received valsartan, HCTZ, or lisinopril were 20%, 19%, and 69% respectively (p&lt;0.001).</p>
<p>Other adverse reactions, not listed above, occurring in &gt;0.2% of patients in controlled clinical trials with valsartan are:</p>
<p><span class="Bold Italics">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></p>
<p><span class="Bold Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span></p>
<p><span class="Bold Italics">Neurologic and Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span></p>
<p><span class="Bold Italics">Respiratory:</span><span class="Bold Italics"> </span><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span></p>
<p><span class="Bold Italics">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span></p>
<p>Other reported events seen less frequently in clinical trials were: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p>Adverse reactions reported for valsartan for indications other than <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> may be found in the prescribing information for Diovan.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6p2"></a><a name="section-6.2"></a><p></p>
<h2>
<span class="Bold">6.2 </span><span class="Bold">Post</span><span class="Bold">m</span><span class="Bold">arketing Experience</span>
</h2>
<p class="First"><span class="Bold Italics">Amlodipine:</span> <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> has been reported infrequently and a causal relationship is uncertain. <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> and hepatic enzyme elevations (mostly consistent with <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>), in some cases severe enough to require hospitalization, have been reported in association with use of amlodipine.</p>
<p><span class="Bold Italics">Valsartan: </span>The following additional adverse reactions have been reported in postmarketing experience with valsartan:</p>
<p><span class="Bold Italics">Blood and Lymphatic: </span>There are very rare reports of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> There are rare reports of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p><span class="Bold Italics">Digestive: </span>Elevated liver enzymes and very rare reports of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span></p>
<p><span class="Bold Italics">Renal:</span> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span></p>
<p><span class="Bold Italics">Clinical Laboratory Tests:</span> <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></p>
<p><span class="Bold Italics">Dermatologic: </span><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></p>
<p><span class="Bold Italics">Vascular:</span>  <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span></p>
<p>Rare cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients receiving angiotensin II receptor blockers. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1>
<span class="Bold">7</span><span class="Bold">  </span><span class="Bold">DRUG INTERACTIONS</span>
</h1>
<div class="Section" data-sectionCode="34073-7">
<a name="s7p1"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">7.1 Drug/Drug Interactions</span></h2>
<p class="First">No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components, as described below: </p>
<p><span class="Bold">Studies with Amlodipine</span></p>
<p>In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. </p>
<p><span class="Bold Italics">Cimetidine:</span> Co-administration of amlodipine with cimetidine did not alter the pharmacokinetics of amlodipine. </p>
<p><span class="Bold Italics">Grapefruit juice: </span>Co-administration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine. </p>
<p><span class="Bold Italics">Maalox</span><span class="Bold Italics"><span class="Sup">®</span></span><span class="Bold Italics"> (antacid):</span> Co-administration of the antacid Maalox with a single dose of amlodipine had no significant effect on the pharmacokinetics of amlodipine. </p>
<p><span class="Bold Italics">Sildenafil:</span> A single 100 mg dose of sildenafil (Viagra<span class="Sup">®</span>**) in subjects with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> had no effect on the pharmacokinetic parameters of amlodipine. When amlodipine and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect. </p>
<p><span class="Bold Italics">Atorvastatin:</span> Co-administration of multiple 10 mg doses of amlodipine with 80 mg of atorvastatin resulted in no significant change in the steady state pharmacokinetic parameters of atorvastatin. </p>
<p><span class="Bold Italics">Digoxin:</span> Co-administration of amlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers. </p>
<p><span class="Bold Italics">Warfarin:</span> Co-administration of amlodipine with warfarin did not change the warfarin <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> response time. </p>
<p><span class="Bold Italics">Simvastatin: </span>Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone.  Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.</p>
<p><span class="Bold">Studies with Valsartan</span></p>
<p>No clinically significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were observed when valsartan was co-administered with amlodipine, atenolol, cimetidine, digoxin, furosemide, glyburide, hydrochlorothiazide, or indomethacin. The valsartan-atenolol combination was more antihypertensive than either component, but it did not lower the heart rate more than atenolol alone. </p>
<p><span class="Bold Italics">Warfarin:</span> Co-administration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin. </p>
<p><span class="Bold Italics">Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)</span><span class="Bold Italics">:  </span>In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including valsartan, may result in deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.  These effects are usually reversible.  Monitor renal function periodically in patients receiving valsartan and NSAID therapy.  </p>
<p>The antihypertensive effect of angiotensin II receptor antagonists, including valsartan may be attenuated by NSAIDs including selective COX-2 inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7p2"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold">7.2 CYP 450 Interactions</span></h2>
<p class="First"><span class="Italics">In vitro</span> metabolism studies indicate that CYP 450 mediated drug interactions between valsartan and co-administered drugs are unlikely because of low extent of metabolism [see <span class="Italics">Pharmacokinetics, Valsartan</span> (12.3)].  As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients to increases in serum creatinine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7p3"></a><a name="section-7.3"></a><p></p>
<h2>
<span class="Bold">7.3 </span><span class="Bold">Transporters</span>
</h2>
<p class="First">The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and the hepatic efflux transporter MRP2.  Co-administration of inhibitors of the uptake transporter (rifampin, cyclosporine) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7p4"></a><a name="section-7.4"></a><p></p>
<h2><span class="Bold">7.4 Clinical Laboratory Findings</span></h2>
<p class="First"><span class="Bold Italics">Creatinine</span><span class="Bold Italics">:</span><span class="Bold Italics"> </span>In hypertensive patients, greater than 50% increases in creatinine occurred in 0.4% of patients receiving Exforge and 0.6% receiving placebo. In <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients, greater than 50% increases in creatinine were observed in 3.9% of valsartan-treated patients compared to 0.9% of placebo-treated patients. In post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> patients, doubling of serum creatinine was observed in 4.2% of valsartan-treated patients and 3.4% of captopril-treated patients.</p>
<p><span class="Bold Italics">Liver Function Tests</span><span class="Bold Italics">:</span> Occasional elevations (greater than 150%) of liver chemistries occurred in Exforge-treated patients.</p>
<p><span class="Bold Italics">Serum Potassium</span><span class="Bold Italics">:</span> In hypertensive patients, greater than 20% increases in serum potassium were observed in 2.8% of Exforge-treated patients compared to 3.4% of placebo-treated patients. In <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients, greater than 20% increases in serum potassium were observed in 10% of valsartan-treated patients compared to 5.1% of placebo-treated patients. </p>
<p><span class="Bold Italics">Blood Urea Nitrogen (BUN)</span><span class="Bold Italics">:</span> In hypertensive patients, greater than 50% increases in BUN were observed in 5.5% of Exforge-treated patients compared to 4.7% of placebo-treated patients. In <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients, greater than 50% increases in BUN were observed in 16.6% of valsartan-treated patients compared to 6.3% of placebo-treated patients. </p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>:</span>  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> was observed in 1.9% of patients treated with Diovan and 0.8% of patients treated with placebo.  </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s8"></a><a name="section-8"></a><p></p>
<h1>
<span class="Bold">8</span><span class="Bold">  </span><span class="Bold">USE IN SPECIFIC POPULATIONS</span>
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s8p1"></a><a name="section-8.1"></a><p></p>
<h2><span class="Bold">8.1 Pregnancy</span></h2>
<p class="First">Pregnancy Category D [see <span class="Italics">W</span><span class="Italics">arnings and</span><span class="Italics"> P</span><span class="Italics">recautions</span><span class="Italics"> (5.1)</span>]</p>
<p>Exforge, like other drugs that act on the renin angiotensin system, can cause fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> when used during the second or third trimester of pregnancy. Exforge can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>Angiotensin II receptor antagonists, like valsartan, and angiotensin converting enzyme (ACE) inhibitors exert similar effects on the renin-angiotensin system. In several dozen published cases, ACE inhibitor use during the second and third trimesters of pregnancy was associated with fetal and neonatal injury, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, neonatal skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, reversible or <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">Oligohydramnios</span> was also reported, presumably from decreased fetal renal function. In this setting, <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> was associated with fetal limb <span class="product-label-link" type="condition" conceptid="4208264" conceptname="Muscle contracture">contractures</span>, craniofacial deformation, and hypoplastic lung development. <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">Prematurity</span>, <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">intrauterine growth retardation</span>, and <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> were also reported, although it is not clear whether these occurrences were due to exposure to the drug. In a retrospective study, first trimester use of ACE inhibitors, a specific class of drugs acting on the renin angiotensin system, was associated with a potential risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>.</p>
<p>When pregnancy occurs in a patient using Exforge, the physician should discontinue Exforge treatment as soon as possible. The physician should inform the patient about potential risks to the fetus based on the time of gestational exposure to Exforge (first trimester only or later). If exposure occurs beyond the first trimester, an ultrasound examination should be done.</p>
<p>In rare cases when another antihypertensive agent cannot be used to treat the pregnant patient, serial ultrasound examinations should be performed to assess the intraamniotic environment. Routine fetal testing with non-stress tests, biophysical profiles, and/or contraction stress tests may be appropriate based on gestational age and standards of care in the community. If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> occurs in these situations, individualized decisions about continuing or discontinuing Exforge treatment and about pregnancy management should be made by the patient, her physician, and experts in the management of high risk pregnancy. Patients and physicians should be aware that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury.</p>
<p>Infants with histories of <span class="Italics">in utero </span>exposure to Exforge should be closely observed for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> occurs, these infants may require blood pressure and renal perfusion support. Exchange transfusion or dialysis may be required to reverse <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or support decreased renal function.</p>
<p>Healthcare professionals who prescribe drugs acting directly on the renin angiotensin system should counsel women of childbearing potential about the risks of these agents during pregnancy [see <span class="Italics">Nonclincial Toxicology (13.2)</span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s8p2"></a><a name="section-8.2"></a><p></p>
<h2><span class="Bold">8.2 Labor and Delivery</span></h2>
<p class="First">The effect of Exforge on labor and delivery has not been studied.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s8p3"></a><a name="section-8.3"></a><p></p>
<h2><span class="Bold">8.3 Nursing Mothers</span></h2>
<p class="First">It is not known whether amlodipine is excreted in human milk. In the absence of this information, it is recommended that nursing be discontinued while amlodipine is administered. </p>
<p>It is not known whether valsartan is excreted in human milk. Valsartan was excreted into the milk of lactating rats; however, animal breast milk drug levels may not accurately reflect human breast milk levels. Because many drugs are excreted into human milk and because of the potential for adverse reactions in nursing infants from Exforge, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s8p4"></a><a name="section-8.4"></a><p></p>
<h2><span class="Bold">8.4 Pediatric Use</span></h2>
<p class="First">Safety and effectiveness of Exforge in pediatric patients have not been established. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s8p5"></a><a name="section-8.5"></a><p></p>
<h2><span class="Bold">8.5 Geriatric Use</span></h2>
<p class="First">In controlled clinical trials, 323 (22.5%) hypertensive patients treated with Exforge were ≥65 years and 79 (5.5%) were ≥75 years. No overall differences in the efficacy or safety of Exforge was observed in this patient population, but greater sensitivity of some older individuals cannot be ruled out. </p>
<p><span class="Bold">Amlodipine:</span> Clinical studies of amlodipine besylate tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. Elderly patients have decreased clearance of amlodipine with a resulting increase of AUC of approximately 40-60%, and a lower initial dose may be required [see <span class="Italics">Dosage and Administration</span><span class="Italics"> </span><span class="Italics">(2.1)</span>].</p>
<p><span class="Bold">Valsartan:</span> In the controlled clinical trials of valsartan, 1,214 (36.2%) of hypertensive patients treated with valsartan were ≥65 years and 265 (7.9%) were ≥75 years. No overall difference in the efficacy or safety of valsartan was observed in this patient population, but greater sensitivity of some older individuals cannot be ruled out. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>
<span class="Bold">10</span><span class="Bold">  </span><span class="Bold">OVERDOSAGE</span>
</h1>
<p class="First"><span class="Bold">Information on Amlodipine</span></p>
<p>Single oral doses of amlodipine maleate equivalent to 40 mg/kg and 100 mg/kg amlodipine in mice and rats, respectively, caused <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. Single oral doses equivalent to 4 or more mg/kg amlodipine in dogs (11 or more times the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis) caused a marked peripheral vasodilation and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. </p>
<p>Overdosage might be expected to cause excessive peripheral vasodilation with marked <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In humans, experience with intentional overdosage of amlodipine is limited. Reports of intentional overdosage include a patient who ingested 250 mg and was asymptomatic and was not hospitalized; another (120 mg) who was hospitalized underwent gastric lavage and remained normotensive; the third (105 mg) was hospitalized and had <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (90/50 mmHg) which normalized following plasma expansion. A case of accidental drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has been documented in a 19-month-old male who ingested 30 mg amlodipine (about 2 mg/kg). During the emergency room presentation, vital signs were stable with no evidence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, but a heart rate of 180 bpm. Ipecac was administered 3.5 hours after ingestion and on subsequent observation (overnight) no sequelae was noted. </p>
<p>If massive <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should occur, active cardiac and respiratory monitoring should be instituted. Frequent blood pressure measurements are essential. Should <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occur, cardiovascular support including elevation of the extremities and the judicious administration of fluids should be initiated. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> remains unresponsive to these conservative measures, administration of vasopressors (such as phenylephrine) should be considered with attention to circulating volume and urine output. Intravenous calcium gluconate may help to reverse the effects of calcium entry blockade. As amlodipine is highly protein bound, hemodialysis is not likely to be of benefit. </p>
<p><span class="Bold">Information on Valsartan</span></p>
<p>Limited data are available related to overdosage in humans. The most likely effect of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with valsartan would be peripheral vasodilation, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> could occur from parasympathetic (vagal) stimulation. <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">Depressed level of consciousness</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> have been reported. If symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> should occur, supportive treatment should be instituted. </p>
<p>Valsartan is not removed from the plasma by hemodialysis.</p>
<p>Valsartan was without grossly observable adverse effects at single oral doses up to 2000 mg/kg in rats and up to 1000 mg/kg in marmosets, except for the <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in the rat and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in the marmoset at the highest dose (60 and 37 times, respectively, the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis). (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.) </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>
<span class="Bold">11</span><span class="Bold">  </span><span class="Bold">DESCRIPTION</span>
</h1>
<p class="First">Exforge is a fixed combination of amlodipine and valsartan.</p>
<p>Exforge contains the besylate salt of amlodipine, a dihydropyridine calcium-channel blocker (CCB). Amlodipine besylate is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow crystalline powder, slightly soluble in water and sparingly soluble in ethanol. Amlodipine besylate’s chemical name is 3-Ethyl-5-methyl(4RS)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate; its structural formula is</p>
<p><img alt="Amlodipine besylate structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=15ba7c1c-dd10-4d09-b6e2-284c1b67f4da&amp;name=exforge-05.jpg"></p>
<p>Its empirical formula is C<span class="Sub">20</span>H<span class="Sub">25</span>ClN<span class="Sub">2</span>O<span class="Sub">5</span>•C<span class="Sub">6</span>H<span class="Sub">6</span>O<span class="Sub">3</span>S and its molecular weight is 567.1. </p>
<p>Valsartan is a nonpeptide, orally active, and specific angiotensin II antagonist acting on the AT<span class="Sub">1</span> receptor subtype. Valsartan is a white to practically white fine powder, soluble in ethanol and methanol and slightly soluble in water. Valsartan’s chemical name is N-(1-oxopentyl)-N-[[2’-(1H-tetrazol-5-yl) [1,1’-biphenyl]-4-yl]methyl]-L-valine; its structural formula is</p>
<p><img alt="Valsartan structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=15ba7c1c-dd10-4d09-b6e2-284c1b67f4da&amp;name=exforge-06.jpg"></p>
<p>Its empirical formula is C<span class="Sub">24</span>H<span class="Sub">29</span>N<span class="Sub">5</span>O<span class="Sub">3</span> and its molecular weight is 435.5.</p>
<p>Exforge tablets are formulated in four strengths for oral administration with a combination of amlodipine besylate, equivalent to 5 mg or 10 mg of amlodipine free-base, with 160 mg, or 320 mg of valsartan providing for the following available combinations: 5/160 mg, 10/160 mg, 5/320 mg, and 10/320 mg. </p>
<p>The inactive ingredients for all strengths of the tablets are colloidal silicon dioxide, crospovidone, magnesium stearate and microcrystalline cellulose. Additionally the 5/320 mg and 10/320 mg strengths contain iron oxide yellow and sodium starch glycolate. The film coating contains hypromellose, iron oxides, polyethylene glycol, talc and titanium dioxide. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>
<span class="Bold">12</span><span class="Bold">  </span><span class="Bold">CLINICAL PHARMACOLOGY</span>
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2><span class="Bold">12.1 Mechanism of Action</span></h2>
<p class="First"><span class="Bold">Amlodipine</span></p>
<p>Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected <span class="Italics">in vitro </span>but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine. Within the physiologic pH range, amlodipine is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect.</p>
<p>Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and reduction in blood pressure. </p>
<p><span class="Bold">Valsartan</span></p>
<p>Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT<span class="Sub">1</span> receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis.</p>
<p>There is also an AT<span class="Sub">2</span> receptor found in many tissues, but AT<span class="Sub">2</span> is not known to be associated with cardiovascular homeostasis. Valsartan has much greater affinity (about 20,000-fold) for the AT<span class="Sub">1</span> receptor than for the AT<span class="Sub">2</span> receptor. The increased plasma levels of angiotensin following AT<span class="Sub">1</span> receptor blockade with valsartan may stimulate the unblocked AT<span class="Sub">2</span> receptor. The primary metabolite of valsartan is essentially inactive with an affinity for the AT<span class="Sub">1</span> receptor about one-200<span class="Sup">th</span> that of valsartan itself. </p>
<p>Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE. Because valsartan does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Valsartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p>
<p>Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of valsartan on blood pressure. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2><span class="Bold">12.2 Pharmacodynamics</span></h2>
<p class="First"><span class="Bold">Amlodipine</span></p>
<p>Following administration of therapeutic doses to patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, amlodipine produces vasodilation resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing. Although the acute intravenous administration of amlodipine decreases arterial blood pressure and increases heart rate in hemodynamic studies of patients with chronic stable angina, chronic oral administration of amlodipine in clinical trials did not lead to clinically significant changes in heart rate or blood pressures in normotensive patients with angina.</p>
<p>With chronic once daily administration, antihypertensive effectiveness is maintained for at least 24 hours. Plasma concentrations correlate with effect in both young and elderly patients. The magnitude of reduction in blood pressure with amlodipine is also correlated with the height of pretreatment elevation; thus, individuals with moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic pressure 105-114 mmHg) had about a 50% greater response than patients with mild <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic pressure 90-104 mmHg). Normotensive subjects experienced no clinically significant change in blood pressure (+1/-2 mmHg). </p>
<p>In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and an increase in glomerular filtration rate and effective renal plasma flow without change in filtration fraction or <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>. </p>
<p>As with other calcium channel blockers, hemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have generally demonstrated a small increase in <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. In hemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and man, even when co-administered with beta-blockers to man. Similar findings, however, have been observed in normals or well-compensated patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with agents possessing significant negative inotropic effects. </p>
<p>Amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals or man. In patients with chronic stable angina, intravenous administration of 10 mg did not significantly alter A-H and H-V conduction and sinus node recovery time after pacing. Similar results were obtained in patients receiving amlodipine and concomitant beta-blockers. In clinical studies in which amlodipine was administered in combination with beta-blockers to patients with either <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or angina, no adverse effects of electrocardiographic parameters were observed. In clinical trials with angina patients alone, amlodipine therapy did not alter electrocardiographic intervals or produce higher degrees of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV blocks</span>.</p>
<p>Amlodipine has indications other than <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> which can be found in the Norvasc* package insert. </p>
<p><span class="Bold">Valsartan</span></p>
<p>Valsartan inhibits the pressor effect of angiotensin II infusions. An oral dose of 80 mg inhibits the pressor effect by about 80% at peak with approximately 30% inhibition persisting for 24 hours. No information on the effect of larger doses is available. </p>
<p>Removal of the negative feedback of angiotensin II causes a 2- to 3-fold rise in plasma renin and consequent rise in angiotensin II plasma concentration in hypertensive patients. Minimal decreases in plasma aldosterone were observed after administration of valsartan; very little effect on serum potassium was observed. </p>
<p>In multiple dose studies in hypertensive patients with stable <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and patients with <span class="product-label-link" type="condition" conceptid="317895" conceptname="Renovascular hypertension">renovascular hypertension</span>, valsartan had no clinically significant effects on glomerular filtration rate, filtration fraction, creatinine clearance, or renal plasma flow. </p>
<p>Administration of valsartan to patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> results in a significant reduction of sitting, supine, and standing systolic blood pressure, usually with little or no orthostatic change. Valsartan has indications other than <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> which can be found in the Diovan package insert. </p>
<p><span class="Bold">Exforge</span></p>
<p>Exforge has been shown to be effective in lowering blood pressure. Both amlodipine and valsartan lower blood pressure by reducing peripheral resistance, but calcium influx blockade and reduction of angiotensin II <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> are complementary mechanisms. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.3"></a><p></p>
<h2><span class="Bold">12.3 Pharmacokinetics</span></h2>
<p class="First"><span class="Bold">Amlodipine</span></p>
<p>Peak plasma concentrations of amlodipine are reached 6-12 hours after administration of amlodipine alone. Absolute bioavailability has been estimated to be between 64% and 90%. The bioavailability of amlodipine is not altered by the presence of food. </p>
<p>The apparent volume of distribution of amlodipine is 21 L/kg. Approximately 93% of circulating amlodipine is bound to plasma proteins in hypertensive patients.</p>
<p>Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine.</p>
<p>Elimination of amlodipine from the plasma is biphasic with a terminal elimination half-life of about 30-50 hours. Steady state plasma levels of amlodipine are reached after 7-8 days of consecutive daily dosing. </p>
<p><span class="Bold">Valsartan</span></p>
<p>Following oral administration of valsartan alone peak plasma concentrations of valsartan are reached in 2-4 hours. Absolute bioavailability is about 25% (range 10%-35%). Food decreases the exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (C<span class="Sub">max</span>) by about 50%.</p>
<p>The steady state volume of distribution of valsartan after intravenous administration is 17 L indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (95%), mainly serum albumin. </p>
<p>Valsartan shows bi-exponential decay kinetics following intravenous administration with an average elimination half-life of about 6 hours. The recovery is mainly as unchanged drug, with only about 20% of dose recovered as metabolites. The primary metabolite, accounting for about 9% of dose, is valeryl 4-hydroxy valsartan. In vitro metabolism studies involving recombinant CYP 450 enzymes indicated that the CYP 2C9 isoenzyme is responsible for the formation of valeryl-4-hydroxy valsartan.  Valsartan does not inhibit CYP 450 isozymes at clinically relevant concentrations.  CYP 450 mediated drug interaction between valsartan and co-administered drugs are unlikely because of the low extent of metabolism.  </p>
<p>Valsartan, when administered as an oral solution, is primarily recovered in feces (about 83% of dose) and urine (about 13% of dose). Following intravenous administration, plasma clearance of valsartan is about 2 L/h and its renal clearance is 0.62 L/h (about 30% of total clearance). </p>
<p><span class="Bold">Exforge</span></p>
<p>Following oral administration of Exforge in normal healthy adults, peak plasma concentrations of valsartan and amlodipine are reached in 3 and 6-8 hours, respectively. The rate and extent of absorption of valsartan and amlodipine from Exforge are the same as when administered as individual tablets.  The bioavailabilities of amlodipine and valsartan are not altered by the co-administration of food.  </p>
<p><span class="Bold">Special Populations</span></p>
<p><span class="Bold Italics">Geriatric</span></p>
<p><span class="Bold Italics">Studies with Amlodipine</span><span class="Italics">:</span> Elderly patients have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40%-60%; therefore a lower initial dose of amlodipine may be required. </p>
<p><span class="Bold Italics">Studies with Valsartan</span><span class="Italics">:</span> Exposure (measured by AUC) to valsartan is higher by 70% and the half-life is longer by 35% in the elderly than in the young. No dosage adjustment is necessary. </p>
<p><span class="Bold Italics">Gender</span></p>
<p><span class="Bold Italics">Studies with Valsartan:</span> Pharmacokinetics of valsartan does not differ significantly between males and females.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></p>
<p><span class="Bold Italics">Studies with Amlodipine:</span> The pharmacokinetics of amlodipine is not significantly influenced by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> may therefore receive the usual initial dose. </p>
<p><span class="Bold Italics">Studies with Valsartan:</span> There is no apparent correlation between renal function (measured by creatinine clearance) and exposure (measured by AUC) to valsartan in patients with different degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Consequently, dose adjustment is not required in patients with mild-to-moderate renal dysfunction. No studies have been performed in patients with severe impairment of renal function (creatinine clearance &lt;10 mL/min). Valsartan is not removed from the plasma by hemodialysis. In the case of severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, exercise care with dosing of valsartan. </p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></p>
<p><span class="Bold Italics">Studies with Amlodipine:</span> Patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> have decreased clearance of amlodipine with resulting increase in AUC of approximately 40%-60%; therefore, a lower initial dose of amlodipine may be required. </p>
<p><span class="Bold Italics">Studies with Valsartan:</span> On average, patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> have twice the exposure (measured by AUC values) to valsartan of healthy volunteers (matched by age, sex and weight). In general, no dosage adjustment is needed in patients with mild-to-moderate liver disease. Care should be exercised in patients with liver disease. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>
<span class="Bold">13</span><span class="Bold">  </span><span class="Bold">NONCLINICAL TOXICOLOGY</span>
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>
<span class="Bold">13.1 Carcinogenesis</span><span class="Bold">,</span><span class="Bold"> Mutagenesis</span><span class="Bold">,</span><span class="Bold"> Impairment of Fertility</span>
</h2>
<p class="First"><span class="Bold Italics">Studies with </span><span class="Bold Italics">A</span><span class="Bold Italics">mlodipine </span></p>
<p>Rats and mice treated with amlodipine maleate in the diet for up to two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg amlodipine/kg/day, showed no evidence of a carcinogenic effect of the drug. For the mouse, the highest dose was, on mg/m<span class="Sup">2</span> basis, similar to the maximum recommended human dose [MRHD] of 10 mg amlodipine/day. For the rat, the highest dose was, on a mg/m<span class="Sup">2</span> basis, about two and a half times the MRHD. (Calculations based on a 60 kg patient.)</p>
<p>Mutagenicity studies conducted with amlodipine maleate revealed no drug-related effects at either the gene or chromosome level. </p>
<p>There was no effect on the fertility of rats treated orally with amlodipine maleate (males for 64 days and females for 14 days prior to mating) at doses of up to 10 mg amlodipine/kg/day (about 10 times the MRHD of 10 mg/day on a mg/m<span class="Sup">2</span> basis). </p>
<p><span class="Bold Italics">Studies with </span><span class="Bold Italics">V</span><span class="Bold Italics">alsartan</span></p>
<p>There was no evidence of carcinogenicity when valsartan was administered in the diet to mice and rats for up to 2 years at concentrations calculated to provide doses of up to 160 and 200 mg/kg/day, respectively. These doses in mice and rats are about 2.4 and 6 times, respectively, the MRHD of 320 mg/day on a mg/m<span class="Sup">2</span> basis. (Calculations based on a 60 kg patient.) </p>
<p>Mutagenicity assays did not reveal any valsartan-related effects at either the gene or chromosome level. These assays included bacterial mutagenicity tests with <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> and E. coli, a gene mutation test with Chinese hamster V79 cells, a cytogenetic test with Chinese hamster ovary cells, and a rat micronucleus test. </p>
<p>Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses of up to 200 mg/kg/day. This dose is about 6 times the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2>
<span class="Bold">13.3 Developmental Toxicity </span><span class="Bold">Studies</span>
</h2>
<p class="First"><span class="Bold Italics">Studies with </span><span class="Bold Italics">A</span><span class="Bold Italics">mlodipine</span> </p>
<p>No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or other embryo/fetal toxicity was found when pregnant rats and rabbits were treated orally with amlodipine maleate at doses of up to 10 mg amlodipine/kg/day (respectively, about 10 and 20 times the maximum recommended human dose [MRHD] of 10 mg amlodipine on a mg/m<span class="Sup">2</span> basis) during their respective periods of major organogenesis. (Calculations based on a patient weight of 60 kg.) However, litter size was significantly decreased (by about 50%) and the number of intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> was significantly increased (about 5-fold) for rats receiving amlodipine maleate at a dose equivalent to 10 mg amlodipine/kg/day for 14 days before mating and throughout mating and gestation. Amlodipine maleate has been shown to prolong both the gestation period and the duration of labor in rats at this dose. There are no adequate and well-controlled studies in pregnant women. Amlodipine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
<p><span class="Bold Italics">Studies with </span><span class="Bold Italics">V</span><span class="Bold Italics">alsartan </span></p>
<p>No teratogenic effects were observed when valsartan was administered to pregnant mice and rats at oral doses of up to 600 mg/kg/day and to pregnant rabbits at oral doses of up to 10 mg/kg/day. However, significant decreases in fetal weight, pup birth weight, pup survival rate, and slight delays in developmental milestones were observed in studies in which parental rats were treated with valsartan at oral, maternally toxic (reduction in body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption) doses of 600 mg/kg/day during organogenesis or late gestation and lactation. In rabbits, fetotoxicity (i.e., resorptions, litter loss, abortions, and low body weight) associated with maternal toxicity (mortality) was observed at doses of 5 and 10 mg/kg/day. The no observed adverse effect doses of 600, 200 and 2 mg/kg/day in mice, rats and rabbits, respectively, are about 9, 6 and 0.1 times the MRHD of 320 mg/day on a mg/m<span class="Sup">2</span> basis. (Calculations based on a patient weight of 60 kg.)</p>
<p><span class="Bold Italics">Studies with </span><span class="Bold Italics">A</span><span class="Bold Italics">mlodipine </span><span class="Bold Italics">B</span><span class="Bold Italics">esylate and </span><span class="Bold Italics">V</span><span class="Bold Italics">alsartan </span></p>
<p>In the oral embryo-fetal development study in rats using amlodipine besylate plus valsartan at doses equivalent to 5 mg/kg/day amlodipine plus 80 mg/kg/day valsartan, 10 mg/kg/day amlodipine plus 160 mg/kg/day valsartan, and 20 mg/kg/day amlodipine plus 320 mg/kg/day valsartan, treatment-related maternal and fetal effects (<span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span> and alterations noted in the presence of significant maternal toxicity) were noted with the high dose combination. The no-observed-adverse-effect level (NOAEL) for embryo-fetal effects was 10 mg/kg/day amlodipine plus 160 mg/kg/day valsartan. On a systemic exposure [AUC<span class="Sub">(0-∞)</span>] basis, these doses are, respectively, 4.3 and 2.7 times the systemic exposure [AUC<span class="Sub">(0-∞)</span>] in humans receiving the MRHD (10/320 mg/60 kg). </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>
<span class="Bold">14</span><span class="Bold">  </span><span class="Bold">CLINICAL STUDIES</span>
</h1>
<p class="First">Exforge was studied in 2 placebo-controlled and 4 active-controlled trials in hypertensive patients. In a double-blind, placebo controlled study, a total of 1,012 patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> received treatments of three combinations of amlodipine and valsartan (5/80, 5/160, 5/320 mg) or amlodipine alone (5 mg), valsartan alone (80, 160, or 320 mg) or placebo. All doses with the exception of the 5/320 mg dose were initiated at the randomized dose. The high dose was titrated to that dose after a week at a dose of 5/160 mg. At week 8, the combination treatments were statistically significantly superior to their monotherapy components in reduction of diastolic and systolic blood pressures.</p>
<table>
<caption><span>Table 1: Effect of Exforge on Sitting Diastolic Blood Pressure </span></caption>
<col width="84">
<col width="60">
<col width="72">
<col width="72">
<col width="72">
<col width="71">
<col width="73">
<col width="64">
<col width="68">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Amlodipine dosage</span></td>
<td class="Lrule Rrule Toprule" align="center" colspan="8"><span class="Bold">Valsartan dosage</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="2">0 mg</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2">80 mg</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2">160 mg</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2">320 mg</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center">Mean Change*</td>
<td class="Lrule Rrule Toprule" align="center">Placebo-subtracted</td>
<td class="Lrule Rrule Toprule" align="center">Mean Change*</td>
<td class="Lrule Rrule Toprule" align="center">Placebo-subtracted</td>
<td class="Lrule Rrule Toprule" align="center">Mean Change*</td>
<td class="Lrule Rrule Toprule" align="center">Placebo-subtracted</td>
<td class="Lrule Rrule Toprule" align="center">Mean Change*</td>
<td class="Lrule Rrule Toprule" align="center">Placebo-subtracted</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">0 mg</td>
<td class="Lrule Rrule Toprule" align="center">-6.4</td>
<td class="Lrule Rrule Toprule" align="center">---</td>
<td class="Lrule Rrule Toprule" align="center">-9.5</td>
<td class="Lrule Rrule Toprule" align="center">-3.1</td>
<td class="Lrule Rrule Toprule" align="center">-10.9</td>
<td class="Lrule Rrule Toprule" align="center">-4.5</td>
<td class="Lrule Rrule Toprule" align="center">-13.2</td>
<td class="Lrule Rrule Toprule" align="center">-6.7</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="center">5 mg</td>
<td class="Lrule Rrule Toprule" align="center">-11.1</td>
<td class="Lrule Rrule Toprule" align="center">-4.7</td>
<td class="Lrule Rrule Toprule" align="center">-14.2</td>
<td class="Lrule Rrule Toprule" align="center">-7.8</td>
<td class="Lrule Rrule Toprule" align="center">-14.0</td>
<td class="Lrule Rrule Toprule" align="center">-7.6</td>
<td class="Lrule Rrule Toprule" align="center">-15.7</td>
<td class="Lrule Rrule Toprule" align="center">-9.3</td>
</tr>
</tbody>
</table>
<p>*Mean Change and Placebo-Subtracted Mean Change from Baseline (mmHg) at Week 8 in Sitting Diastolic Blood Pressure. Mean baseline diastolic BP was 99.3 mmHg.</p>
<table>
<caption><span>Table 2: Effect of Exforge on Sitting Systolic Blood Pressure</span></caption>
<col width="84">
<col width="57">
<col width="77">
<col width="63">
<col width="77">
<col width="63">
<col width="77">
<col width="63">
<col width="77">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center"> <span class="Bold">Amlodipine dosage</span> </td>
<td class="Lrule Rrule Toprule" align="center" colspan="8"> <span class="Bold">Valsartan dosage</span> </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> 0 mg </td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> 80 mg </td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> 160 mg </td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> 320 mg </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">   </td>
<td class="Lrule Rrule Toprule" align="center"> Mean Change* </td>
<td class="Lrule Rrule Toprule" align="center"> Placebo-subtracted </td>
<td class="Lrule Rrule Toprule" align="center"> Mean Change* </td>
<td class="Lrule Rrule Toprule" align="center"> Placebo-subtracted </td>
<td class="Lrule Rrule Toprule" align="center"> Mean Change* </td>
<td class="Lrule Rrule Toprule" align="center"> Placebo-subtracted </td>
<td class="Lrule Rrule Toprule" align="center"> Mean Change* </td>
<td class="Lrule Rrule Toprule" align="center"> Placebo-subtracted </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center"> 0 mg </td>
<td class="Lrule Rrule Toprule" align="center"> -6.2 </td>
<td class="Lrule Rrule Toprule" align="center"> --- </td>
<td class="Lrule Rrule Toprule" align="center"> -12.9 </td>
<td class="Lrule Rrule Toprule" align="center"> -6.8 </td>
<td class="Lrule Rrule Toprule" align="center"> -14.3 </td>
<td class="Lrule Rrule Toprule" align="center"> -8.2 </td>
<td class="Lrule Rrule Toprule" align="center"> -16.3 </td>
<td class="Lrule Rrule Toprule" align="center"> -10.1 </td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="center"> 5 mg </td>
<td class="Lrule Rrule Toprule" align="center"> -14.8 </td>
<td class="Lrule Rrule Toprule" align="center"> -8.6 </td>
<td class="Lrule Rrule Toprule" align="center"> -20.7 </td>
<td class="Lrule Rrule Toprule" align="center"> -14.5 </td>
<td class="Lrule Rrule Toprule" align="center"> -19.4 </td>
<td class="Lrule Rrule Toprule" align="center"> -13.2 </td>
<td class="Lrule Rrule Toprule" align="center"> -22.4 </td>
<td class="Lrule Rrule Toprule" align="center"> -16.2 </td>
</tr>
</tbody>
</table>
<p>*Mean Change and Placebo-Subtracted Mean Change from Baseline (mmHg) at Week 8 in Sitting Systolic Blood Pressure. Mean baseline systolic BP was 152.8 mmHg.</p>
<p>In a double-blind, placebo controlled study, a total of 1,246 patients with mild to moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> received treatments of two combinations of amlodipine and valsartan (10/160, 10/320 mg) or amlodipine alone (10 mg), valsartan alone (160 or 320 mg) or placebo. With the exception of the 10/320 mg dose, treatment was initiated at the randomized dose. The high dose was initiated at a dose of 5/160 mg and titrated to the randomized dose after 1 week. At week 8, the combination treatments were statistically significantly superior to their monotherapy components in reduction of diastolic and systolic blood pressures.</p>
<table>
<caption><span>Table 3: Effect of Exforge on Sitting Diastolic Blood Pressure</span></caption>
<col width="119">
<col width="75">
<col width="77">
<col width="75">
<col width="77">
<col width="75">
<col width="77">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center"> <span class="Bold">Amlodipine dosage</span> </td>
<td class="Lrule Rrule Toprule" align="center" colspan="6"> <span class="Bold">Valsartan dosage</span> </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> 0 mg </td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> 160 mg </td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> 320 mg </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center"> Mean Change* </td>
<td class="Lrule Rrule Toprule" align="center"> Placebo-subtracted </td>
<td class="Lrule Rrule Toprule" align="center"> Mean Change* </td>
<td class="Lrule Rrule Toprule" align="center"> Placebo-subtracted </td>
<td class="Lrule Rrule Toprule" align="center"> Mean Change* </td>
<td class="Lrule Rrule Toprule" align="center"> Placebo-subtracted </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center"> 0 mg </td>
<td class="Lrule Rrule Toprule" align="center"> -8.2 </td>
<td class="Lrule Rrule Toprule" align="center"> --- </td>
<td class="Lrule Rrule Toprule" align="center"> -12.8 </td>
<td class="Lrule Rrule Toprule" align="center"> - 4.5 </td>
<td class="Lrule Rrule Toprule" align="center"> -12.8 </td>
<td class="Lrule Rrule Toprule" align="center"> -4.5 </td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="center"> 10 mg </td>
<td class="Lrule Rrule Toprule" align="center"> -15.0 </td>
<td class="Lrule Rrule Toprule" align="center"> -6.7 </td>
<td class="Lrule Rrule Toprule" align="center"> - 17.2 </td>
<td class="Lrule Rrule Toprule" align="center"> - 9.0 </td>
<td class="Lrule Rrule Toprule" align="center"> -18.1 </td>
<td class="Lrule Rrule Toprule" align="center"> -9.9 </td>
</tr>
</tbody>
</table>
<p>*Mean Change and Placebo-Subtracted Mean Change from Baseline (mmHg) at Week 8 in Sitting Diastolic Blood Pressure. Mean baseline diastolic BP was 99.1 mmHg.</p>
<table>
<caption><span>Table 4: Effect of Exforge on Sitting Systolic Blood Pressure</span></caption>
<col width="105">
<col width="72">
<col width="85">
<col width="72">
<col width="85">
<col width="72">
<col width="85">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center">
<span class="Bold">Amlodipine dosage</span> </td>
<td class="Lrule Rrule Toprule" align="center" colspan="6"> <span class="Bold">Valsartan dosage</span> </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> 0 mg </td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> 160 mg </td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> 320 mg </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center"> Mean Change* </td>
<td class="Lrule Rrule Toprule" align="center"> Placebo-subtracted </td>
<td class="Lrule Rrule Toprule" align="center"> Mean Change* </td>
<td class="Lrule Rrule Toprule" align="center"> Placebo-subtracted </td>
<td class="Lrule Rrule Toprule" align="center"> Mean Change* </td>
<td class="Lrule Rrule Toprule" align="center"> Placebo-subtracted </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center"> 0 mg </td>
<td class="Lrule Rrule Toprule" align="center"> -11.0 </td>
<td class="Lrule Rrule Toprule" align="center"> --- </td>
<td class="Lrule Rrule Toprule" align="center"> -18.1 </td>
<td class="Lrule Rrule Toprule" align="center"> -7.0 </td>
<td class="Lrule Rrule Toprule" align="center"> -18.5 </td>
<td class="Lrule Rrule Toprule" align="center"> -7.5 </td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="center"> 10 mg </td>
<td class="Lrule Rrule Toprule" align="center"> -22.2 </td>
<td class="Lrule Rrule Toprule" align="center"> -11.2 </td>
<td class="Lrule Rrule Toprule" align="center"> -26.6 </td>
<td class="Lrule Rrule Toprule" align="center"> -15.5 </td>
<td class="Lrule Rrule Toprule" align="center"> -26.9 </td>
<td class="Lrule Rrule Toprule" align="center"> -15.9 </td>
</tr>
</tbody>
</table>
<p>*Mean Change and Placebo-Subtracted Mean Change from Baseline (mmHg) at Week 8 in Sitting Systolic Blood Pressure. Mean baseline systolic BP was 156.7 mmHg.</p>
<p>In a double-blind, active-controlled study, a total of 947 patients with mild to moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> who were not adequately controlled on valsartan 160 mg received treatments of two combinations of amlodipine and valsartan (10/160, 5/160 mg), or valsartan alone (160 mg). At week 8, the combination treatments were statistically significantly superior to the monotherapy component in reduction of diastolic and systolic blood pressures.</p>
<table>
<caption><span>Table 5: Effect of Exforge on Sitting Diastolic/Systolic Blood Pressure</span></caption>
<col width="151">
<col width="108">
<col width="108">
<col width="108">
<col width="96">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"> Treatment Group </td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> Diastolic BP </td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> Systolic BP  </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center"> Mean change* </td>
<td class="Lrule Rrule Toprule" align="center"> Treatment Difference** </td>
<td class="Lrule Rrule Toprule" align="center"> Mean change* </td>
<td class="Lrule Rrule Toprule" align="center"> Treatment Difference** </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"> Exforge<br> 10/160 mg </td>
<td class="Lrule Rrule Toprule" align="center"> -11.4 </td>
<td class="Lrule Rrule Toprule" align="center"> -4.8 </td>
<td class="Lrule Rrule Toprule" align="center"> -13.9 </td>
<td class="Lrule Rrule Toprule" align="center"> -5.7 </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"> Exforge <br> 5/160 mg </td>
<td class="Lrule Rrule Toprule" align="center"> -9.6 </td>
<td class="Lrule Rrule Toprule" align="center"> -3.1 </td>
<td class="Lrule Rrule Toprule" align="center"> -12.0 </td>
<td class="Lrule Rrule Toprule" align="center"> -3.9 </td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule"> Valsartan 160 mg </td>
<td class="Lrule Rrule Toprule" align="center"> -6.6 </td>
<td class="Lrule Rrule Toprule" align="center"> --- </td>
<td class="Lrule Rrule Toprule" align="center"> -8.2 </td>
<td class="Lrule Rrule Toprule" align="center"> --- </td>
</tr>
</tbody>
</table>
<p>*Mean Change from Baseline at Week 8 in Sitting Diastolic/Systolic Blood Pressure. Mean baseline BP was 149.5/96.5 (systolic/diastolic) mmHg</p>
<p>**Treatment Difference = difference in mean BP reduction between Exforge and the control group (Valsartan 160 mg) </p>
<p>In a double-blind, active-controlled study, a total of 944 patients with mild to moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> who were not adequately controlled on amlodipine 10 mg received a combination of amlodipine and valsartan (10/160 mg), or amlodipine alone (10 mg). At week 8, the combination treatment was statistically significantly superior to the monotherapy component in reduction of diastolic and systolic blood pressures.</p>
<table>
<caption><span>Table 6: Effect of Exforge on Sitting Diastolic/Systolic Blood Pressure</span></caption>
<col width="151">
<col width="108">
<col width="108">
<col width="108">
<col width="96">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"> Treatment Group </td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> Diastolic BP </td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> Systolic BP  </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule">Mean change* </td>
<td class="Lrule Rrule Toprule"> Treatment Difference** </td>
<td class="Lrule Rrule Toprule"> Mean change* </td>
<td class="Lrule Rrule Toprule"> Treatment Difference** </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"> Exforge<br> 10/160 mg </td>
<td class="Lrule Rrule Toprule" align="center"> -11.8 </td>
<td class="Lrule Rrule Toprule" align="center"> -1.8 </td>
<td class="Lrule Rrule Toprule" align="center"> -12.7 </td>
<td class="Lrule Rrule Toprule" align="center"> -1.9 </td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule"> Amlodipine 10 mg </td>
<td class="Lrule Rrule Toprule" align="center"> -10.0 </td>
<td class="Lrule Rrule Toprule" align="center"> --- </td>
<td class="Lrule Rrule Toprule" align="center"> -10.8 </td>
<td class="Lrule Rrule Toprule" align="center"> --- </td>
</tr>
</tbody>
</table>
<p>*Mean Change from Baseline at Week 8 in Sitting Diastolic/Systolic Blood Pressure. Mean baseline BP was 147.0/95.1 (systolic/diastolic) mmHg</p>
<p>**Treatment Difference = difference in mean BP reduction between Exforge and the control group (Amlodipine 10 mg) </p>
<p>Exforge was also evaluated for safety in a 6-week, double-blind, active-controlled trial of 130 hypertensive patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (mean baseline BP of 171/113 mmHg). Adverse events were similar in patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and mild/moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> treated with Exforge. </p>
<p>A wide age range of the adult population, including the elderly was studied (range 19-92 years, mean 54.7 years). Women comprised almost half of the studied population (47.3%). Of the patients in the studied Exforge group, 87.6% were Caucasian. Black and Asian patients each represented approximately 4% of the population in the studied Exforge group. </p>
<p>Two additional double-blind, active-controlled studies were conducted in which Exforge was administered as initial therapy. In one study, a total of 572 Black patients with moderate to severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> were randomized to receive either combination amlodipine/valsartan or amlodipine monotherapy for 12 weeks. The initial dose of amlodipine/valsartan was 5/160 mg for 2 weeks with forced titration to 10/160 mg for 2 weeks, followed by optional titration to 10/320 mg for 4 weeks and optional addition of HCTZ 12.5 mg for 4 weeks. The initial dose of amlodipine was 5 mg for 2 weeks with forced titration to 10 mg for 2 weeks, followed by optional titration to 10 mg for 4 weeks and optional addition of HCTZ 12.5 mg for 4 weeks. At the primary endpoint of 8 weeks, the treatment difference between amlodipine/valsartan and amlodipine was 6.7/2.8 mmHg. </p>
<p>In the other study of similar design, a total of 646 patients with moderate to severe hypertension (MSSBP of ≥ 160 mmHg and &lt;200 mmHg) were randomized to receive either combination amlodipine/valsartan or amlodipine monotherapy for 8 weeks. The initial dose of amlodipine/valsartan was 5/160 mg for 2 weeks with forced titration to 10/160 mg for 2 weeks, followed by the optional addition of HCTZ 12.5 mg for 4 weeks. The initial dose of amlodipine was 5 mg for 2 weeks with forced titration to 10 mg for 2 weeks, followed by the optional addition of HCTZ 12.5 mg for 4 weeks. At the primary endpoint of 4 weeks, the treatment difference between amlodipine/valsartan and amlodipine was 6.6/3.9 mmHg. </p>
<p>There are no trials of the Exforge combination tablet demonstrating reductions in cardiovascular risk in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, but the amlodipine component and several ARBs, which are the same pharmacological class as the valsartan component, have demonstrated such benefits.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>
<span class="Bold">16</span><span class="Bold">  </span><span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span>
</h1>
<p class="First">Exforge is available as non-scored tablets containing amlodipine besylate equivalent to 5 mg, or 10 mg of amlodipine free-base with valsartan 160 mg or 320 mg, providing for the following available combinations: 5/160 mg, 10/160 mg, 5/320 mg and 10/320 mg.</p>
<p><br></p>
<p>5/160 mg Tablets - dark yellow, ovaloid shaped, film coated tablet
with beveled edge, debossed with “NVR? on one side and “ECE? on the
other side. </p>
<a name="i284d863a-204f-4c2c-80a0-2702a2318eb1"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-5997-0<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 90<br>
</td>
<td>NDC 54868-5997-1<br>
</td>
</tr>
</tbody></table>
<p>10/160
mg Tablets - light yellow, ovaloid shaped, film coated tablet with
beveled edge, debossed with “NVR? on one side and “UIC? on the other
side.</p>
<a name="i56adaf48-1bc4-4689-876d-72c598e7ebf5"></a><table width="30%"><tbody class="Headless"><tr class="First Last">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-5804-0<br>
</td>
</tr></tbody></table>
<p>5/320
mg Tablets - very dark yellow, ovaloid shaped, film coated tablet with
beveled edge, debossed with “NVR? on one side and “CSF? on the other
side.</p>
<a name="i293be12f-9fe0-4a58-815b-aa2de435e8df"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-5996-0<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 90<br>
</td>
<td>NDC 54868-5996-1<br>
</td>
</tr>
</tbody></table>
<p>10/320
mg Tablets - dark yellow, ovaloid shaped, film coated tablet with
beveled edge, debossed with “NVR? on one side and “LUF? on the other
side.</p>
<a name="ifb3a42e1-2c96-492f-8223-b5582913b9d5"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-5983-0<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 90<br>
</td>
<td>NDC 54868-5983-1</td>
</tr>
</tbody></table>
<p>Store at 25<span class="Sup">o</span>C (77<span class="Sup">o</span>F); excursions permitted to 15-30<span class="Sup">o</span>C (59-86<span class="Sup">o</span>F). [See USP Controlled Room Temperature.] Protect from moisture. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>
<span class="Bold">17</span><span class="Bold">  </span><span class="Bold">PATIENT COUNSELING INFORMATION</span>
</h1>
<p class="First"><span class="Bold">Information for Patients</span></p>
<p><span class="Bold Italics">Pregnancy:</span> Female patients of childbearing age should be told that use of drugs like valsartan that act on the renin-angiotensin system can cause serious problems in the fetus and infant including: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span>, poor development of skull bones, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Discuss other treatment options with female patients planning to become pregnant. Women using Exforge who become pregnant should notify their physicians as soon as possible. </p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">FDA-APPROVED PATIENT LABELING</span></p>
<p>PATIENT INFORMATION</p>
<p>EXFORGE (X-phorj)</p>
<p>(amlodipine and valsartan) </p>
<p>Tablets</p>
<p>Read the Patient Information that comes with EXFORGE before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or treatment. If you have any questions about EXFORGE, ask your doctor or pharmacist.</p>
<a name="ifd3d752c-ab37-4ef0-8550-5d0b2abefc20"></a><table>
<col width="734">
<tbody class="Headless"><tr class="First Last"><td class="Lrule Rrule Toprule">
<span class="Bold">What is the most important information I should know about EXFORGE?</span><br><span class="Bold">If you become pregnant, stop taking EXFORGE and call your doctor right away. EXFORGE can harm an unborn baby causing injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> If you plan to become pregnant, talk to your doctor about other treatment options to lower your blood pressure before taking EXFORGE.</td></tr></tbody>
</table>
<p><span class="Bold">What is EXFORGE?</span></p>
<p>EXFORGE contains two prescription medicines: </p>
<ol class="Arabic">
<li>amlodipine, a calcium channel blocker<br>
</li>
<li>valsartan, an angiotensin receptor blocker (ARB). </li>
</ol>
<p>EXFORGE may be used to lower high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>) in adults</p>
<ul class="Disc">
<li>when one medicine to lower your high blood pressure is not enough<br>
</li>
<li>as the first medicine to lower high blood pressure if your doctor decides you are likely to need more than one medicine.</li>
</ul>
<p>EXFORGE has not been studied in children under 18 years of age.</p>
<p><span class="Bold">What should I tell my doctor before taking EXFORGE?</span></p>
<p>Tell your doctor about all of your medical conditions, including if you: </p>
<ul class="Disc">
<li>
<span class="Bold">are pregnant or plan to become pregnant.</span> See “What is the most important information I should know about EXFORGE??<br>
</li>
<li>
<span class="Bold">are breast-feeding or plan to breast-feed.</span> EXFORGE may pass into your milk. Do not breast-feed while you are taking EXFORGE.<br>
</li>
<li>have heart problems<br>
</li>
<li>have liver problems<br>
</li>
<li>have kidney problems<br>
</li>
<li>are <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or having a lot of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </li>
</ul>
<p>Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Some of your other medicines and EXFORGE could affect each other, causing serious side effects. </p>
<p>Especially tell your doctor if you take: </p>
<ul class="Disc">
<li>other medicines for high blood pressure or a heart problem<br>
</li>
<li>water pills (diuretics) <br>
</li>
<li>potassium supplements<br>
</li>
<li>a salt substitute<br>
</li>
<li>nonsteroidal anti-inflammatory drugs (like ibuprofen or naproxen)</li>
</ul>
<p>Know the medicines you take. Keep a list of your medicines and show it to your doctor or pharmacist when you get a new medicine. Talk to your doctor or pharmacist before you start taking any new medicine. Your doctor or pharmacist will know what medicines are safe to take together.</p>
<p><span class="Bold">How should I take EXFORGE?</span></p>
<ul class="Disc">
<li>Take EXFORGE exactly as your doctor tells you. <br>
</li>
<li>Take EXFORGE once each day. <br>
</li>
<li>EXFORGE can be taken with or without food.<br>
</li>
<li>If you miss a dose, take it as soon as you remember. If it is close to your next dose, do not take the missed dose. Just take the next dose at your regular time. <br>
</li>
<li>If you take too much EXFORGE, call your doctor or Poison Control Center, or go to the emergency room.<br>
</li>
<li>Tell all your doctors or dentist you are taking EXFORGE if you: <br>      ○   are going to have surgery<br>      ○   go for kidney dialysis</li>
</ul>
<p><span class="Bold">What should I avoid while taking Exforge?</span></p>
<p>You should not take Exforge during pregnancy. See “What is the most important information I should know about Exforge.?</p>
<p><span class="Bold">What are the possible side effects of EXFORGE?</span></p>
<p>EXFORGE may cause <span class="Bold">serious side effects</span> including:</p>
<ul class="Disc">
<li>
<span class="Bold">harm to an unborn baby causing injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span><span class="Bold">. </span>See “What is the most important information I should know about EXFORGE??<br>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>)</span>. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> is most likely to happen if you: <br>
</li>
<li>take water pills<br>
</li>
<li>are on a low salt diet<br>
</li>
<li>get dialysis treatments<br>
</li>
<li>have heart problems <br>
</li>
<li>get sick with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span><br>
</li>
<li>drink alcohol</li>
</ul>
<p>Lie down if you feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> or dizzy. Call your doctor right away. </p>
<ul class="Disc">
<li>
<span class="Bold">more <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (angina) </span>in people that already have severe heart problems. This may happen when you start EXFORGE or when there is an increase in your dose of EXFORGE. Get emergency help if you get worse <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> that does not go away. <br>
</li>
<li>
<span class="Bold">kidney problems.</span> Kidney problems may become worse in people that already have kidney disease. Some people will have changes in blood tests for kidney function and may need a lower dose of EXFORGE. Call your doctor if you have <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your feet, ankles, or hands or unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. If you have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, your doctor should check your kidney function before prescribing EXFORGE.<br>
</li>
<li>
<span class="Bold">laboratory blood test changes in people with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span></span>. Some people with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> who take valsartan, one of the medicines in EXFORGE, have changes in blood tests including increased potassium and decreased kidney function. </li>
</ul>
<p>The most common side effects of EXFORGE include:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>) of the hands, ankles, or feet 
		     
	<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> when swallowing <br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> (head or chest <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>)<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of EXFORGE. For more information, ask your doctor or pharmacist. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How should I store EXFORGE?</span></p>
<ul class="Disc">
<li>Store EXFORGE at room temperature between 59°F to 86°F (15°C to 30°C). <br>
</li>
<li>Keep EXFORGE dry (protect it from moisture). </li>
</ul>
<p><span class="Bold">Keep EXFORGE and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General Information about EXFORGE</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in the patient information leaflet. Do not use EXFORGE for a condition for which it was not prescribed. Do not give EXFORGE to other people, even if they have the same symptoms that you have. It may harm them. </p>
<p>This patient information leaflet summarizes the most important information about EXFORGE. If you would like more information about EXFORGE, talk with your doctor. You can ask your doctor or pharmacist for information about EXFORGE that is written for health professionals. For more information go to www.EXFORGE.com or call 1-888-839-3674.</p>
<p><span class="Bold">What are the ingredients in EXFORGE?</span></p>
<p>Active ingredients: Amlodipine besylate and valsartan </p>
<p>The inactive ingredients of all strengths of the tablets are colloidal silicon dioxide, crospovidone, magnesium stearate and microcrystalline cellulose. Additionally, the 5/320 mg and 10/320 mg strengths contain iron oxide yellow and sodium starch glycolate. The film coating contains hypromellose, iron oxides, polyethylene glycol, talc and titanium dioxide.</p>
<p><span class="Bold">What is high blood pressure (h</span><span class="Bold">ypertension)?</span></p>
<p>Blood pressure is the force of blood in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too much. EXFORGE can help your blood vessels relax so your blood pressure is lower. Medicines that lower blood pressure lower your chance of having a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. </p>
<p>High blood pressure makes the heart work harder to pump blood throughout the body and causes damage to blood vessels. If high blood pressure is not treated, it can lead to <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> and vision problems. </p>
<p>*Norvasc<span class="Sup">®</span> is a registered trademark of Pfizer, Inc.</p>
<p>**Viagra<span class="Sup">®</span> is a registered trademark of Pfizer, Inc.</p>
<p>Distributed by:</p>
<p>Novartis Pharmaceuticals Corporation</p>
<p>East Hanover, New Jersey 07936</p>
<p>©Novartis</p>
<p>T2011-133/T2011-69<br>October 2011/April 2011</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<p class="First"><span class="Bold">Relabeling and Repackaging by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma     74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label – 5 mg*/160 mg</span></p>
<p>Rx Only
		     
	
		      <br></p>
<p>EXFORGE® (amlodipine and valsartan) Tablets</p>
<p><br></p>
<p>*each tablet contains 6.9 mg of amlodipine besylate</p>
<p><img alt="PRINCIPAL DISPLAY PANEL – PACKAGE LABEL – 5 MG*/160 MG TABLETS" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=15ba7c1c-dd10-4d09-b6e2-284c1b67f4da&amp;name=5997.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label – 10 mg*/160 mg</span></p>
<p>Rx Only
		     
	
		      <br></p>
<p>EXFORGE® (amlodipine and valsartan) Tablets</p>
<p><br></p>
<p>*each tablet contains 13.9 mg of amlodipine besylate</p>
<p><img alt="PRINCIPAL DISPLAY PANEL – PACKAGE LABEL – 10 MG*/160 MG TABLETS" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=15ba7c1c-dd10-4d09-b6e2-284c1b67f4da&amp;name=5804.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label – 5 mg*/320 mg</span></p>
<p>Rx Only
		     
	
		      <br></p>
<p>EXFORGE® (amlodipine and valsartan) Tablets</p>
<p><br></p>
<p>*each tablet contains 6.9 mg of amlodipine besylate</p>
<p><img alt="PRINCIPAL DISPLAY PANEL – PACKAGE LABEL – 5 MG*/320 MG TABLETS" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=15ba7c1c-dd10-4d09-b6e2-284c1b67f4da&amp;name=5996.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label – 10 mg*/320 mg</span></p>
<p>Rx Only
		     
	
		      <br></p>
<p>EXFORGE® (amlodipine and valsartan) Tablets</p>
<p><br></p>
<p>*each tablet contains 13.9 mg of amlodipine besylate</p>
<p><img alt="PRINCIPAL DISPLAY PANEL – PACKAGE LABEL – 10 MG*/320 MG TABLETS" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=15ba7c1c-dd10-4d09-b6e2-284c1b67f4da&amp;name=5983.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EXFORGE 		
					</strong><br><span class="contentTableReg">amlodipine besylate and valsartan tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5997(NDC:0078-0488)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>VALSARTAN</strong> (VALSARTAN) </td>
<td class="formItem">VALSARTAN</td>
<td class="formItem">160 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (dark yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (ovaloid shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NVR;ECE</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5997-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5997-1</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021990</td>
<td class="formItem">03/05/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EXFORGE 		
					</strong><br><span class="contentTableReg">amlodipine besylate and valsartan tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5804(NDC:0078-0489)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>VALSARTAN</strong> (VALSARTAN) </td>
<td class="formItem">VALSARTAN</td>
<td class="formItem">160 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (light yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (ovaloid shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NVR;UIC</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5804-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021990</td>
<td class="formItem">08/15/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EXFORGE 		
					</strong><br><span class="contentTableReg">amlodipine besylate and valsartan tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5996(NDC:0078-0490)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>VALSARTAN</strong> (VALSARTAN) </td>
<td class="formItem">VALSARTAN</td>
<td class="formItem">320 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (very dark yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (ovaloid shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NVR;CSF</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5996-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5996-1</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021990</td>
<td class="formItem">03/05/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EXFORGE 		
					</strong><br><span class="contentTableReg">amlodipine besylate and valsartan tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5983(NDC:0078-0491)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>VALSARTAN</strong> (VALSARTAN) </td>
<td class="formItem">VALSARTAN</td>
<td class="formItem">320 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (dark yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (ovaloid shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NVR;LUF</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5983-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5983-1</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021990</td>
<td class="formItem">06/22/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>99fc81a8-679b-46b6-900f-7207a878f6df</div>
<div>Set id: 15ba7c1c-dd10-4d09-b6e2-284c1b67f4da</div>
<div>Version: 6</div>
<div>Effective Time: 20120111</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
